|
 GSK said on Feb. 18 that it had paused a late-stage trial, dubbed
"GRACE," as well as two other studies, based on safety
recommendations from an independent committee but did not give
further details on what had prompted the recommendations.
RSV is a leading cause of pneumonia in toddlers and the elderly, but
vaccine development has been plagued by setbacks for decades.
However, many drugmakers are now working to bring a candidate to the
market over the next few years.
GSK, the world's biggest vaccine maker by sales, reiterated on
Monday that the halts did not affect another trial of its RSV
vaccine candidate for adults aged 60 and over, adding that analysis
of the safety data from the maternal trials is ongoing.
[to top of second column] |
 RSV vaccines are seen as an opportunity for GSK
to deliver on pledges to boost its drug
development success rate, where it has long
lagged industry peers. GSK's shot for pregnant
women was aimed at conferring immunity to
protect unborn children.
Its vaccine for the elderly, another major
vulnerable population, has been regarded by
analysts as a potential big RSV market, with
trial results expected in the first half this
year.
(Reporting by Pushkala Aripaka in Bengaluru;
Editing by Anil D'Silva)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
